Bristol Myers Squibb (CELG-RI) Operating Margin (2009 - 2026)
Bristol Myers Squibb (CELG-RI) reported Operating Margin of 1.58% for Q1 2026, down 103.0% year-over-year from 52.8% in Q1 2025, and up 92.46% quarter-over-quarter from 21.01% in Q4 2025.
Bristol Myers Squibb (CELG-RI) Operating Margin (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has 18 years of Operating Margin data on file, last reported at 1.58% in Q1 2026.
- Operating Margin for Q1 2026 came in at 1.58%, down 103.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 9.75% (up 696.0% YoY), and the FY2025 annual result was 9.56%, up 3671.0% from the prior year.
- Operating Margin grew to 1.58% in Q1 2026 per CELG-RI's latest filing, from 21.01% in the prior quarter.
- Over five years, Operating Margin peaked at 1.8% in Q1 2023 and troughed at 121.77% in Q1 2024.
- A 5-year average of 15.65% and a median of 6.73% in 2022 frame the typical range for Operating Margin.
- The sharpest annual moves came in 2024 and 2025: Operating Margin slumped 12357 bps in 2024, then surged 12122 bps in 2025.
- A 5-year view of Operating Margin shows it stood at 6.44% in 2022, then plunged by 45 bps to 9.33% in 2023, then sank by 303 bps to 37.57% in 2024, then surged by 44 bps to 21.01% in 2025, then soared by 92 bps to 1.58% in 2026.
- Business Quant data shows CELG-RI's Operating Margin at 1.58% in Q1 2026, 21.01% in Q4 2025, and 2.63% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 30.06% |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 47.98% |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 26.44% |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 26.60% |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -47.46% |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 30.94% |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 37.16% |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | -286.83% |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | -1.58% |
| 10 | Bristol Myers Squibb | - | - | 8.07 Bn | -1.58% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.58% |
| Dec 31, 2025 | -21.01% |
| Sep 30, 2025 | -2.63% |
| Jun 30, 2025 | -13.03% |
| Mar 31, 2025 | -0.55% |
| Dec 31, 2024 | -37.57% |
| Sep 30, 2024 | -10.77% |
| Jun 30, 2024 | -16.24% |
| Mar 31, 2024 | -121.77% |
| Dec 31, 2023 | -9.33% |
| Sep 30, 2023 | -3.36% |
| Jun 30, 2023 | -9.06% |
| Mar 31, 2023 | 1.80% |
| Dec 31, 2022 | -6.44% |
| Sep 30, 2022 | -1.28% |
| Jun 30, 2022 | -6.41% |
| Mar 31, 2022 | -6.73% |
| Dec 31, 2021 | -4.16% |
| Sep 30, 2021 | -1.15% |
| Jun 30, 2021 | -7.68% |